Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis

Molecular Pharmaceutics

Volumn 6, Issue 2, 2009, Pages 634-640

  Doschak, Michael R ^a,c   Kucharski, Cezary M ^a   Wright, Jennifer E I ^a   Zernicke, Ronald F ^b   Uludag, Hasan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Department of Orthopaedic Surgery ^*  (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anterior cruciate ligament; Bisphosphonate; Bone remodeling; Bone targeting; Osteoarthritis; Osteoprotegerin

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HYDROXYAPATITE; OSTEOPROTEGERIN; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BINDING AFFINITY; BONE REMODELING; CONJUGATE; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMUR; IN VITRO STUDY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; TIBIA; TRABECULAR BONE;

ANIMALS; BONE AND BONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; OSTEOARTHRITIS; OSTEOPROTEGERIN; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 64649100407     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8002368     Document Type: Article

References (23)

1. Abramson, S. B.; Honig, S. Antiresorptive agents and osteoarthritis: more than a bone to pick. Arthritis Rheum. 2007, 56, 2469-73.
2. Vega, D.; Maalouf, N. M.; Sakhaee, K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/os-teoprotegerin: clinical implications. J. Clin. Endocrinol. Metab. 2007, 92, 4514-21.
3. Boyle, W. J.; Simonet, W. S.; Lacey, D. L. Osteoclast differentiation and activation. Nature 2003, 423, 337-42.
4. Ominsky, M. S.; Li, X.; Asuncion, F. J.; Barrero, M.; Warmington, K. S.; Dwyer, D.; Stolina, M.; Geng, Z.; Grisanti, M.; Tan, H. L.; Corbin, T.; McCabe, J.; Simonet, W. S.; Ke, H. Z.; Kostenuik, P. J. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner. Res. 2008, 23, 672-82.
5. Smith, B. B.; Cosenza, M. E.; Mancini, A.; Dunstan, C.; Gregson, R.; Martin, S. W.; Smith, S. Y.; Davis, H. A toxicity profile of osteoprotegerin in the cynomolgus monkey. Int. J. Toxicol. 2003, 22, 403-12.
6. Liu, W.; Feng, W.; Wang, F.; Li, W.; Gao, C.; Zhou, B.; Ma, M. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp. Mol. Pathol. 2008, 84 (3), 213-7.
7. Omland, T.; Ueland, T.; Jansson, A. M.; Persson, A.; Karlsson, T.; Smith, C.; Herlitz, J.; Aukrust, P.; Hartford, M.; Caidahl, K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 2008, 51, 627-33.
8. Zhang, S.; Gangal, G.; Uludaǧ, H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem. Soc. Rev. 2007, 36, 507-31.
9. Gittens, S. A.; Bansal, G.; Kucharski, C.; Borden, M.; Uludag, H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes. Mol. Pharmaceutics 2005, 2, 392-406.
10. Bansal, G.; Wright, J. E.; Zhang, S.; Zernicke, R. F.; Uludag, H. Imparting mineral affinity to proteins with thiol-labile disulfide linkages. J. Biomed. Mater. Res. 2005, 74, 618-28.
11. Uludag, H.; Kousinioris, N.; Gao, T.; Kantoci, D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol. Prog. 2000, 16, 258-67.
12. Hayami, T.; Pickarski, M.; Zhuo, Y.; Wesolowski, G. A.; Rodan, G. A.; Duong, l. T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006, 38, 234-43.
13. Liepe, K.; Geidel, H.; Haase, M.; Hakenberg, O. W.; Runge, R.; Kotzerke, J. New model for the induction of osteoblastic bone metastases in rat. Anticancer Res. 2005, 25, 1067-73.
14. Kumar, V.; Kumar, D.; Howman-Giles, R. B.; Little, D. G. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging? Nucl. Med. Commun. 2007, 28, 101-7.
15. Vitha, T.; Kubícek, V; Hermann, P.; Elst, L. V.; Muller, R. N.; Kolar, Z. I.; Wolterbeek, H. T.; Breeman, W. A.; Lukes, I.; Peters,J. A. Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. J. Med. Chem. 2008, 51, 677-83.
16. Kadri, A.; Ea, H. K.; Bazille, C.; Hannouche, D.; Lioté, F.; Cohen-Solal, M. E. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum. 2008, 58, 2379-86.
17. Shimizu, S.; Asou, Y.; Itoh, S.; Chung, U. I.; Kawaguchi, H.; Shinomiya, K.; Muneta, T. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum. 2007, 56, 3358-65.
18. Hirabayashi, H.; Sawamoto, T.; Fujisaki, J.; Tokunaga, Y.; Kimura, S.; Hata, T. Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS). Pharm Res. 2001, 18, 646-51.
19. Hirabayashi, H.; Takahashi, T.; Fujisaki, J.; Masunaga, T.; Sato, S.; Hiroi, J.; Tokunaga, Y.; Kimura, S.; Hata, T. Bone-specific delivery and sustained release of diclofenac, a nonsteroidal antiinflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J. Controlled Release 2001, 70, 183-91.
20. Zhang, S.; Wright, J. E.; Bansal, G.; Cho, P.; Uludag, H. Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols. Biomacromolecules 2005, 6, 2800-8.
21. Wright, J. E.; Gittens, S. A.; Bansal, G.; Kitov, P. I.; Sindrey, D.; Kucharski, C.; Uludaǧ, H. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials 2006, 27, 769-84.
22. Pan, H.; Liu, J.; Dong, Y.; Sima, M.; Kopecková, P.; Brandi, M. L.; Kopecek, J. Release of prostaglandin E(1) from N-(2-hydroxypropyl) methacrylamide copolymer conjugates by bone cells. Macromol. Biosci. 2008, 8, 599-605.
23. Miller, S. C.; Pan, H.; Wang, D.; Bowman, B. M.; Kopečková, P.; Kopeček, J. Feasibility of Using a Bone-Targeted, Macromo-lecular Delivery System Coupled with Prostaglandin E(1) to Promote Bone Formation in Aged, Estrogen-Deficient Rats. Pharm. Res. 2008, 25, 2889-95.